Purchase Order 75N93023P00983

Award Date 7/21/23
Potential Completion Date 9/29/23
Potential Value $19K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
West Sacramento, CA 95605, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Gemini Bioproducts LLC, a leading manufacturer of cell culture media and reagents, is for the purchase of 60 500 mL bottles of fetal bovine serum (FBS). The $20,130 firm fixed price contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), with a completion date of January 15, 2016. Gemini Bioproducts has a history of providing FBS and other products to federal agencies...
This federal contract award, valued at $77,738.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to Gemini Bioproducts LLC. The contract is for the procurement of a benchmark fetal bovine serum (FBS) lot to support research characterizing the infectious properties of SARS-CoV-2 variants and developing effective prophylactic and therapeutic vaccine candidates. This is a sole source award, as the specified FBS lot...
This $6,336 firm fixed-price purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Gemini Bioproducts LLC, a leading manufacturer and supplier of cell culture media, sera, and other reagents to the scientific community. The contract is for the delivery of Benchmark FBS - 500mL, catalog #100106. Gemini Bioproducts has received numerous prior awards from NIH to supply fetal bovine serum for cell...
This is a $13,451.00 firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH), a civilian federal agency. The contract is for the delivery of fetal bovine serum from Gemini Bioproducts LLC, a for-profit manufacturer and supplier of cell culture media, sera, and other reagents. This award does not have a set-aside designation. Gemini Bioproducts has previously received numerous orders...
This federal contract award to Gemini Bioproducts LLC, a for-profit manufacturer of cell culture media and other biomedical research supplies, is for the delivery of fetal bovine serum under Purchase Order HHSN272201001085P. The $5,027.40 firm fixed price contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the supply of BENCHMARK fetal bovine serum. Gemini Bioproducts has previously received numerous...
This federal contract award was made by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Gemini Bioproducts LLC. The $57,375.00 firm-fixed-price purchase order was for the delivery of 500 mL of benchmark fetal bovine serum, a critical cell culture component used in biomedical research. This order is part of NIAID's ongoing procurement of specialized cell culture media and reagents to support its diverse scientific initiatives....
Gemini Bioproducts LLC was awarded a firm fixed price purchase order totaling $51,066.81 by the National Institutes of Health National Heart Lung and Blood Institute to supply 500ml of Benchmark fetal bovine serum. The award was made non-competitively on February 22, 2019 to fulfill a special notice issued on January 31, 2019 for the specified product. Performance will take place in West Sacramento, California by April 22, 2021. No set-aside designation was applied. Gemini Bioproducts...
This firm fixed-price purchase order was awarded to Gemini Bioproducts LLC, a for-profit manufacturer of goods, by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases. The $102,116.06 contract is for the delivery of fetal bovine serum, and is designated as a Total Small Business set-aside. Gemini Bioproducts is a leading supplier of cell culture media, sera, and other reagents to the scientific community, including...
This federal contract award was made by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Gemini Bioproducts LLC. The $6,165.00 firm fixed-price purchase order is for the delivery of 500 ml bottles of fetal bovine serum, a critical cell culture reagent used in biomedical research and pharmaceutical development. The contract has no set-aside designation. Gemini Bioproducts is a leading manufacturer and supplier of cell culture...
This federal contract award, valued at $9,186.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to Gemini Bioproducts LLC, a leading manufacturer and supplier of cell culture media, sera, and other reagents. The contract is for the delivery of 500 mL bottles of heat-inactivated fetal bovine serum, a critical component for cell culture maintenance across biomedical research and development. The award is not associated with a larger contract vehicle, and there was...

Gemini Bioproducts LLC has been awarded a $19,254.92 firm fixed price purchase order by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to provide Fetal Bovine Serum (FBS), U.S. origin, as described in NIH requisition number 2180219. Performance will occur in West Sacramento, California over a period of two months concluding in late September 2023. The contract action was funded through the Department of Health and Human Services and supports the NIH's ongoing research efforts into allergy and infectious disease under the NIAID's programs. No set aside designation or subcontractors beyond the prime were identified.

Generated 12/19/23, 5:10 PM